Crystalline forms of quetiapine hemifumarate
CA 2479668 A1 · Owner: Lifshitz-Liron, Revital · Inventors: Dolitzky, Ben-Zion; Lidor-Hadas, Rami; Kovalevski-Ishai, Eti
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to novel crystalline forms of quetiapine hemifumarate (I), denominated quetiapine hemifuramate form II and quetiapine hemifuramate form III. These novel crystalline forms of quetiapine hemifuramate have been characterized by methods including x-ray powder diffraction (XRD), Fourier transform IR spectroscopy (FTIR) differential , scanning calorimetry (DSC) and thermal gravimetric analysis (TGA). Methods for preparation of the novel crystalline quetiapine hemifuramate form II as its chloroform solvate and its dichloromethane solvate form III as its , chloroform solvate, and form I are provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 20, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 20, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 20, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.